Liver Transplantation Candidates With COVID-19 Have High Risk for Early Death
Researchers investigated the impact of COVID-19 on patients waiting for liver transplants, as well as on the clinical course following transplantation.
Researchers investigated the impact of COVID-19 on patients waiting for liver transplants, as well as on the clinical course following transplantation.
Study finds that patients with SARS-CoV-2 infection who are solid organ transplant recipients are at increased risk for intensive care unit admission, invasive mechanical ventilation, and mortality.
Researchers conducted a study to determine whether the investigational oral microbiome therapeutic SER-109 decreases the risk for recurrent Clostridioides difficile infection.
Investigators described a syndrome of cholangiopathy in patients recovering from severe COVID-19 with abnormal liver tests and bile duct injury.
More patients receiving mRNA-1273 booster have serologic response with anti-receptor-binding domain antibody level of at least 100 U/mL.
Researchers assessed long-term outcomes of multidrug-resistant Enterobacterales colonization and infections among solid organ transplant recipients.
Favorable outcomes, minimal adverse effects seen in solid organ transplant recipients who received monoclonal antibody therapy for COVID-19.
Johns Hopkins investigators sought to evaluate antibody responses to a second SARS-CoV-2 mRNA vaccine dose among organ transplant recipients.
The NDA submission is supported by data from the multicenter, randomized, open-label, active-controlled phase 3 TAK-620-303 (SOLSTICE) trial.
A woman died of COVID-19 after receiving an infected double-lung transplant.